Free Shipping for all Order of €500
Showing all 3 results
-
Wegovy 0.25 mg Pen (1.5 ml Multi-Dose / Wegovy 0.25 mg/1.5 ml Pen Injector)
172,00 €Pre-filled subcutaneous semaglutide pen containing 1.5 ml total solution (delivering four 0.25 mg weekly doses for Month 1 initiation). Designed for steady metabolic adaptation and appetite control.
What is Wegovy 0.25 mg (1.5 ml Pen)?
Wegovy 0.25 mg (searched as Wegovy 0.25 mg/1.5 ml pen, 0.25 mg Wegovy pen, Wegovy 0 25 mg, or Wegovy 0 25 mg 1.5 ml pen) is the initial starting dose of semaglutide for chronic weight management (Wegovy weight loss 0.25 mg). Pre-filled FlexTouch pens contain 1.5 ml total volume ($0.68\text{ mg/ml}$ concentration, providing 4 weekly doses of $0.25\text{ mg}$ across the 1.5 ml total volume).
Who is it for?
It is indicated for adults with a Body Mass Index (BMI) $\ge 30\text{ kg/m}^2$ (obesity) or $\ge 27\text{ kg/m}^2$ (overweight) accompanied by weight-related comorbidities.
Why start at 0.25 mg?
Initiating treatment with the $0.25\text{ mg}$ dose allows your gastrointestinal tract to adapt smoothly to GLP-1 receptor activation, delayed gastric emptying, and appetite suppression.
-
Wegovy 0.5 mg
170,00 €What is Wegovy 0.5 mg?
Wegovy 0.5 mg is a prescription medication containing semaglutide, a GLP-1 receptor agonist that helps regulate appetite and promote weight loss. It is administered as a once-weekly subcutaneous injection using the pre-filled FlexTouch pen.
Who is it for?
Wegovy is indicated for adults with:
-
BMI ≥ 30 kg/m² (obesity), or
-
BMI ≥ 27 kg/m² (overweight) with at least one weight-related comorbidity such as:
-
Prediabetes or type 2 diabetes
-
Hypertension (high blood pressure)
-
Dyslipidaemia
-
Obstructive sleep apnoea
-
Cardiovascular disease
-
Adolescents (≥12 years): Wegovy is indicated for adolescents with obesity (BMI ≥95th percentile) and body weight above 60 kg.
Why Choose Wegovy?
-
Proven weight loss: Clinical trials show 15-17% average body weight loss at the full 2.4 mg maintenance dose
-
Once-weekly injection: Convenient dosing schedule
-
Cardiovascular benefits: Reduces the risk of major adverse cardiovascular events
-
GLP-1 mechanism: Mimics natural hormones to reduce appetite and food intake
-
-
Wegovy 1 mg | Semaglutide Weight Loss Injection
170,00 €What is Wegovy 1 mg?
Wegovy 1 mg is a prescription medication containing semaglutide, a GLP-1 receptor agonist that helps regulate appetite and promote weight loss. Each FlexTouch pen delivers 1 mg of semaglutide per 0.5 mL injection . It is administered as a once-weekly subcutaneous injection and represents the third dose in the 16-week dose escalation protocol .
Who is it for?
Wegovy is indicated for adults with:
-
BMI ≥ 30 kg/m² (obesity), or
-
BMI ≥ 27 kg/m² (overweight) with at least one weight-related comorbidity such as prediabetes, type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease .
It is also indicated for adolescents aged 12 years and above with obesity and body weight above 60 kg .
Why Choose Wegovy?
-
Proven weight loss: Clinical trials show 15-17% average body weight loss at the maintenance dose of 2.4 mg
-
Once-weekly injection: Convenient dosing with the FlexTouch pen
-
Cardiovascular benefits: Reduces the risk of major adverse cardiovascular events
-
GLP-1 mechanism: Works with your body’s natural appetite regulation system
-
